TVTX · NASDAQ · STOCK
Travere Therapeutics (TVTX) Stock Analysis
$52.12
52W $22.59 – $68.73
52/100
$4.85B
-115.8
1.14
Is TVTX Bullish or Bearish?
Mixed.
Innellis AI committee rates Travere Therapeutics, Inc. (TVTX) Watch with a composite score of 52/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.67 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 77.1% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 77.1% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 29.8x prices in significant intangible value — Value
- ROE of only -55.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.71 adds balance-sheet risk to the value case — Value
- RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.71) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 89%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 29.8x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 77.1% YoY -- genuine top-line momentum
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.71) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.7 to 51.7.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
18.9
Oversold
MACD Histogram
-0.928
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$26.19
Resistance
$60.05
Bollinger %B
0.04
Inside Bands
Price vs Moving Averages
EMA 9
$55.52
Below
EMA 21
$58.55
Below
EMA 50
$59.67
Below
EMA 200
$48.46
Above
Fundamental Analysis
Valuation
66
Growth
72
Profitability
25
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
-115.8×
P/B Ratio
198.70×
PEG Ratio
1.01
Dividend Yield
0.00%
52W High
$68.73
52W Low
$22.59
Quality & Growth
ROE
-2224.7%
ROA
-422.1%
Gross Margin
9440.6%
Operating Margin
-684.2%
Revenue Growth YoY
—
Debt / Equity
25.16
AI Fundamental Assessment
P/E ratio of -115.8 (inexpensive relative to a 15-40x range); Price-to-book of 198.7x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -22.2%; Return on assets of -4.2%; Net margin of -7.4%; Gross margin of 94.4%; Current ratio of 4.05 (healthy short-term liquidity); Debt-to-equity of 25.16; Free cash flow per share is positive (0.55); Most recent quarter beat estimates by 142.4%; EPS growth accelerating (-1433.3% -> +115.0% QoQ); Analyst estimates falling over recent quarters
Get the Full TVTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →